RxDoctor Payments Data

Svetang Desai, MD

Gastroenterology · Houston, TXNPI 1003069733

Payments from drug & device makers

$80,267in general payments, 2019–2025

Across 168 payments — averaging $477.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$75K
  • Nestle Healthcare Nutrition Inc.$4K
  • Intercept Pharmaceuticals, Inc.$121
  • Cook Medical LLC$120
  • Ambu Inc.$114
  • Pfizer$88
  • plus $430 from 13 others

What the payments were for

  • Speaking & faculty fees$74,52593%
  • Travel & lodging$1,7402%
  • Food & beverage$4,0025%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,267 in reported general payments places this provider in the 90th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$187,119
Medicare patients
622
Services billed
1,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase51$338,819
ZenpepLipase/Protease/Amylase26$139,485
Humira(Cf) PenAdalimumab13$88,460
HumiraAdalimumab12$87,204
LinzessLinaclotide34$24,138
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates312$19,522
Mesalamine56$17,410
Alosetron Hcl29$15,526
Pantoprazole Sodium706$9,668
Mesalamine ErMesalamine27$8,383
TrulancePlecanatide15$8,215
Dexlansoprazole DrDexlansoprazole24$8,202
Lubiprostone24$5,930
Budesonide EcBudesonide18$3,685
Sucralfate42$3,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Humira, Linzess$75,090$450,16197 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$38$8,21515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →